Levodopa/Benzerazide ( DrugBank: Levodopa )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01568047 (ClinicalTrials.gov)	February 2010	29/3/2012	Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients	Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet®) or Levodopa/Benserazide 100/25 mg (Madopar®/Restex®) and With Motor Fluctuations (Wearing-off Phenomenon)	Parkinson's Disease	Drug: Placebo;Drug: BIA 9-1067;Drug: Levodopa/Carbidopa;Drug: Levodopa/Benzerazide	Bial - Portela C S.A.	NULL	Completed	30 Years	N/A	All	40	Phase 2	Romania;Ukraine
2	NCT01568034 (ClinicalTrials.gov)	April 2009	29/3/2012	A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067	A Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067 on the Levodopa Pharmacokinetics, Motor Response, and Erythrocyte Soluble Catechol-O-methyltransferase Activity in Parkinson's Disease Patients Concomitantly Treated With Levodopa/Dopa-decarboxylase Inhibitor	Parkinson's Disease	Drug: BIA 9-1067;Drug: Placebo;Drug: Levodopa/Carbidopa;Drug: Levodopa/Benzerazide	Bial - Portela C S.A.	NULL	Completed	30 Years	75 Years	All	10	Phase 2	Portugal;Romania;Ukraine